valproic acid has been researched along with Weight Gain in 98 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy." | 9.08 | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. ( Corman, CL; Guberman, AH; Leung, NM, 1997) |
| " This paper presents an analysis of body weight data gathered during a randomized trial comparing valproate with carbamazepine in 260 children aged 4-15 years with newly-diagnosed epilepsy." | 9.08 | Weight gain with valproate or carbamazepine--a reappraisal. ( Easter, D; O'Bryan-Tear, CG; Verity, C, 1997) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 8.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "To study the association between CYP2C19*2 (681 G > A) and UGT1A6*2 (552A > C) polymorphisms on Valproic acid (VPA)-induced weight gain in People with epilepsy (PWE)." | 8.02 | CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study. ( Kamalanathan, S; Kesavan, R; Mani, B; Nair, PP; Narayan, SK; Sekhar, A, 2021) |
| " We attempted to investigate the influence of CYP2C19 polymorphisms on valproic acid (VPA)-induced weight gain." | 7.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Studies of the effect of oxcarbazepine (OXC) on body growth of children with epilepsy are rare and their results are controversial." | 7.83 | Weight gain in children on oxcarbazepine monotherapy. ( Attilakos, A; Garoufi, A; Katsarou, E; Koemtzidou, E; Kossiva, L; Soldatou, A; Tsentidis, C; Vartzelis, G, 2016) |
| "Weight gain is the most frequent adverse effect of valproic acid (VPA) treatment, resulting in poor compliance and many endocrine disturbances." | 7.81 | Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. ( Chen, X; Chen, Z; Hou, X; Huang, M; Li, H; Li, J; Ni, G; Su, Q; Wang, X; Xie, W; Xin, S; Zhou, L; Zhou, Y, 2015) |
| " The aim of the present study was to determine whether VPA therapy affects leptin and AP circulating levels in prepubertal girls with epilepsy." | 7.77 | Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. ( Balestri, P; Barlocco, EG; Casarosa, E; Grosso, S; Luisi, S; Matera, M; Mostardini, R; Petraglia, F, 2011) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 7.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Valproic acid-associated weight gain may occur in young children." | 7.75 | Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. ( Balestri, P; Grosso, S; Mostardini, R; Piccini, B, 2009) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 7.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 7.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| "This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years." | 7.72 | Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. ( Ayala, R; Dam, M; Gomez, G; Isojärvi, J; Messenheimer, J; Morrell, MJ; O'Neill, F; Taylor, AE; Tennis, P, 2003) |
| "To investigate the possible role of valproic acid therapy in the development of the weight gain and hyperinsulinemia of epileptic patients." | 7.72 | [Insulin resistance in epileptic patients during treatment of valproic acid]. ( Bao, YY; Chen, Z; Ding, MP; Liu, ZR; Xu, LL, 2004) |
| "Valproic acid is effective for treatment of many types of epilepsy, but its use in epileptic patients can be associated with an increase in body weight that could interfere with treatment compliance." | 7.71 | Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. ( Basciani, F; Chiarelli, F; De Simone, M; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure." | 5.72 | The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy. ( Battaglia, D; Blasi, V; DI Ruscio, F; Ferrara, P; Gatto, A, 2022) |
| "Quercetin (50 mg/kg) was administered orally to the animals from gestational days 6." | 5.56 | Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism. ( Baldissarelli, J; de Mattos, BDS; de Souza, AA; Gamaro, GD; Pedra, NS; Soares, MSP; Spanevello, RM; Spohr, L; Stefanello, FM; Teixeira, FC, 2020) |
| "Autism is a severe behavioral disorder characterized by pervasive impairments in social interactions, deficits in verbal and nonverbal communication, and stereotyped, repetitive patterns of behaviors and interests." | 5.33 | Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. ( Przewłocki, R; Schneider, T, 2005) |
| " Valproic acid appears to be use cautionally in obese females with epilepsy." | 5.24 | Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. ( Sadhotra, A; Sidhu, HS; Srinivas, R, 2017) |
| " Weight gain is a significant side effect of valproic acid, which has not been clearly identified pathogenetically." | 5.12 | The role of ghrelin in weight gain and growth in epileptic children using valproate. ( Akinci, A; Gungor, S; Ozerol, IH; Tabel, Y; Yologlu, S; Yücel, G, 2007) |
| "A significant weight gain and increase in serum leptin levels in the course of antiepileptic treatment with valproic acid (VPA) has been described in several clinical studies." | 5.10 | Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. ( Abraham, I; Bauer, G; Hoppichler, F; Lechleitner, M; Luef, G; Trinka, E; Unterberger, I, 2002) |
| " This paper presents an analysis of body weight data gathered during a randomized trial comparing valproate with carbamazepine in 260 children aged 4-15 years with newly-diagnosed epilepsy." | 5.08 | Weight gain with valproate or carbamazepine--a reappraisal. ( Easter, D; O'Bryan-Tear, CG; Verity, C, 1997) |
| "We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy." | 5.08 | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. ( Corman, CL; Guberman, AH; Leung, NM, 1997) |
| " VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance." | 4.89 | Metabolic and endocrine effects of valproic acid chronic treatment. ( Belcastro, V; D'Egidio, C; Striano, P; Verrotti, A, 2013) |
| "In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain." | 4.87 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. ( Chiarelli, F; Coppola, G; D'Egidio, C; Mohn, A; Verrotti, A, 2011) |
| "Valproic acid (VPA), a widely used antiepileptic drug, has broad-spectrum activity against both generalized and partial epilepsy." | 4.85 | Valproate-induced insulin resistance and obesity in children. ( Chiarelli, F; la Torre, R; Mohn, A; Trotta, D; Verrotti, A, 2009) |
| "Valproic acid (2-n-propylpentanoic acid, VPA) is well-established as a mood-stabilizer for bipolar disorder, in addition to its application as a treatment in neurological disorders such as epilepsy, migraine headaches, and chronic neuropathic pain." | 4.84 | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. ( Rasgon, NL; Reynolds, MF; Sisk, EC, 2007) |
| " Weight gain and pharmacokinetic interaction with lamotrigine are perhaps the most consistent problems in use." | 4.82 | Valproate. ( Bowden, CL, 2003) |
| "Although monotherapy with lithium or divalproex is the recommended initial therapy for bipolar disorder, these agents are associated with prolonged favorable outcomes in only 30% of patients." | 4.82 | Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. ( Bowden, CL, 2005) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| "To study the association between CYP2C19*2 (681 G > A) and UGT1A6*2 (552A > C) polymorphisms on Valproic acid (VPA)-induced weight gain in People with epilepsy (PWE)." | 4.02 | CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study. ( Kamalanathan, S; Kesavan, R; Mani, B; Nair, PP; Narayan, SK; Sekhar, A, 2021) |
| "Studies of the effect of oxcarbazepine (OXC) on body growth of children with epilepsy are rare and their results are controversial." | 3.83 | Weight gain in children on oxcarbazepine monotherapy. ( Attilakos, A; Garoufi, A; Katsarou, E; Koemtzidou, E; Kossiva, L; Soldatou, A; Tsentidis, C; Vartzelis, G, 2016) |
| " We attempted to investigate the influence of CYP2C19 polymorphisms on valproic acid (VPA)-induced weight gain." | 3.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Weight gain is the most frequent adverse effect of valproic acid (VPA) treatment, resulting in poor compliance and many endocrine disturbances." | 3.81 | Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. ( Chen, X; Chen, Z; Hou, X; Huang, M; Li, H; Li, J; Ni, G; Su, Q; Wang, X; Xie, W; Xin, S; Zhou, L; Zhou, Y, 2015) |
| " The aim of the present study was to determine whether VPA therapy affects leptin and AP circulating levels in prepubertal girls with epilepsy." | 3.77 | Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. ( Balestri, P; Barlocco, EG; Casarosa, E; Grosso, S; Luisi, S; Matera, M; Mostardini, R; Petraglia, F, 2011) |
| "Increased serum levels of leptin, NPY and galanin play an important role in VPA-associated weight gain in children." | 3.77 | Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate. ( Camurdan, O; Cansu, A; Cinaz, P; Hırfanoğlu, T; Serdaroglu, A, 2011) |
| "This study was undertaken in 2 parts to investigate the relationship between body size and insulin resistance during treatment with valproic acid in children." | 3.76 | Weight gain and insulin resistance in children treated with valproate: the influence of time. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Masuccio, F; Mohn, A; Verrotti, A, 2010) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 3.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight." | 3.75 | Nonalcoholic fatty liver disease during valproate therapy. ( Chiarelli, F; Di Marco, G; la Torre, R; Pelliccia, P; Verrotti, A, 2009) |
| "Valproic acid-associated weight gain may occur in young children." | 3.75 | Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. ( Balestri, P; Grosso, S; Mostardini, R; Piccini, B, 2009) |
| "Chronic antiepileptic therapy with valproic acid (VPA) is associated with increased body weight and insulin resistance in adults and children." | 3.74 | Adiponectin and visfatin concentrations in children treated with valproic acid. ( Ebenbichler, CF; Ernst, B; Haberlandt, E; Hoppichler, F; Karall, D; Luef, G; Rauchenzauner, M; Rostasy, K; Scholl-Bürgi, S, 2008) |
| "To compare the incidence and magnitude of weight gain associated with valproic acid (VPA) monotherapy in male and female epilepsy patients and to determine possible gender-specific differences in frequency of carbohydrate craving, body-composition, glucose homeostasis and lipid metabolism." | 3.74 | Valproate, weight gain and carbohydrate craving: a gender study. ( Bauer, G; El-Khatib, F; Hoppichler, F; Lechleitner, M; Luef, GJ; Naser, A; Rauchenzauner, M; Trinka, E; Unterberger, I; Waldmann, M, 2007) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 3.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 3.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| "This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years." | 3.72 | Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. ( Ayala, R; Dam, M; Gomez, G; Isojärvi, J; Messenheimer, J; Morrell, MJ; O'Neill, F; Taylor, AE; Tennis, P, 2003) |
| "To investigate the possible role of valproic acid therapy in the development of the weight gain and hyperinsulinemia of epileptic patients." | 3.72 | [Insulin resistance in epileptic patients during treatment of valproic acid]. ( Bao, YY; Chen, Z; Ding, MP; Liu, ZR; Xu, LL, 2004) |
| "Valproic acid is effective for treatment of many types of epilepsy, but its use in epileptic patients can be associated with an increase in body weight that could interfere with treatment compliance." | 3.71 | Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. ( Basciani, F; Chiarelli, F; De Simone, M; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "In this experiment, we studied the effect of valproate (VPA) on weight gain, and serum leptin levels in prepubertal epileptic children receiving VPA." | 3.71 | Does long-term use of valproate cause weight gain in prepubertal epileptic children? ( Berberoğlu, M; Caksen, H; Deda, G, 2002) |
| "Weight gain has been recognized as an adverse effect of valproic acid therapy, but there are are no data about serum leptin levels in patients receiving this drug." | 3.70 | Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. ( Basciani, F; Chiarelli, F; de Martino, M; Morgese, G; Morresi, S; Verrotti, A, 1999) |
| "We report on three cases of acutely manic prepubertal children diagnosed with bipolar disorder who were treated with olanzapine in addition to their existing mood stabilizer regimens." | 3.70 | Mood stabilizer augmentation with olanzapine in acutely manic children. ( Chang, KD; Ketter, TA, 2000) |
| " An association between weight gain, obstructive sleep apnea, and lithium treatment is also illustrated." | 3.68 | Four cases of obstructive sleep apnea associated with treatment-resistant mania. ( Alpert, JE; Frankenburg, FR; Hudson, JI; Keck, PE; Strakowski, SM; Teschke, GC; Tohen, M; Wilson, DR, 1991) |
| "Hazard ratios (HR) for time to recurrence were longer for quetiapine plus lithium/divalproex than placebo plus lithium/divalproex for mixed (HR=0." | 2.77 | Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. ( Ekholm, B; Gustafsson, U; Suppes, T; Udd, M; Vieta, E, 2012) |
| "Olanzapine-treated patients had significantly greater increases in weight and in glucose, cholesterol, triglyceride, uric acid, and prolactin levels than divalproex-treated patients." | 2.73 | Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. ( Aaronson, ST; Amsterdam, JD; Banov, M; Bardenstein, L; Bowden, C; Goodwin, GM; Grecu-Gabos, I; Kryzhanovskaya, L; Oliff, HS; Prelipceanu, D; Shekhar, A; Sun, B; Tochilov, V; Tohen, M; Vieta, E, 2008) |
| " Dosing of VPA-ER either once-daily or twice-daily is acceptable." | 2.72 | Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. ( Lehman, EB; McCabe, PH; McNew, CD; Michel, NC, 2006) |
| "Weight gain is a common side effect of valproate treatment." | 2.71 | Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. ( Aydin, K; Bideci, A; Gucuyener, K; Okuyaz, C; Serdaroglu, A, 2005) |
| "Mean weight gain was 10." | 2.70 | Quetiapine alone and added to a mood stabilizer for serious mood disorders. ( Bingham, CR; Brescan, DW; DiGiovanni, SK; Hattab, H; Perez, DE; Ray, JB; Sajatovic, M, 2001) |
| "There was no significant difference in seizure frequency between the two doses." | 2.69 | Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. ( Lundkvist, B; Sundqvist, A; Tomson, T, 1998) |
| "Weight gain is a common side effect of valproate treatment." | 2.69 | Weight gain associated with valproate in childhood. ( Aysun, S; Demir, E, 2000) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Clinicians and caregivers need to be aware of potential endocrine and metabolic adverse effects of psychiatric medications." | 2.43 | Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. ( Carlson, HE; Correll, CU, 2006) |
| "Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure." | 1.72 | The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy. ( Battaglia, D; Blasi, V; DI Ruscio, F; Ferrara, P; Gatto, A, 2022) |
| "Weight gain is the one of the most important factors which increases global burden of psychiatric disorder." | 1.72 | Increased growth hormone secretagogue receptor-1a (GHSR-1a) in hypothalamus during olanzapine treatment in rats. ( Altunkaynak, Z; Bilgici, B; Gümrükçüoğlu, Tİ; Karaustaoğlu, A; Tunçel, ÖK, 2022) |
| "Quercetin (50 mg/kg) was administered orally to the animals from gestational days 6." | 1.56 | Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism. ( Baldissarelli, J; de Mattos, BDS; de Souza, AA; Gamaro, GD; Pedra, NS; Soares, MSP; Spanevello, RM; Spohr, L; Stefanello, FM; Teixeira, FC, 2020) |
| " absence of OLZ/SAM, were within the equivalence interval of 80-125% for both maximum plasma concentration and area under the plasma concentration-time curve over a 12-h dosing interval of lithium and of valproate." | 1.56 | Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate. ( Graham, C; Sun, L; von Moltke, L; Yagoda, S; Yao, B, 2020) |
| "Although some drugs used in the treatment of epilepsy are known to affect body weight, the hormonal factors responsible have not been sufficiently described." | 1.48 | The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children. ( Alver, A; Cansu, A; Çiçek, NP; Kamaşak, T; Okten, A; Serin, M, 2018) |
| " Cosmetic side effects leading to dosage change or discontinuation occurred most frequently with pregabalin and valproic acid compared with all other AEDs (13." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| "Valproic acid was found to have a significant impact on the worsening of BMI from overweight to obesity (P<0." | 1.40 | The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. ( Ching, HY; Wang, PS; Wu, SL, 2014) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| "Weight gain was seen in 66." | 1.36 | Modification in body weight associated with antiepileptic drugs. ( Gaspari, CN; Guerreiro, CA, 2010) |
| "Absence status was aggravated with carbamazepine and generalised tonic-clonic seizures were not controlled with ethosuximide." | 1.36 | Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status. ( Genton, P; Velizarova, R, 2010) |
| "Weight gain is a known side effect of valproate (VPA) therapy, which is associated with hyperinsulinemia and polycystic ovary-like syndrome and unfavorable lipid changes in women." | 1.33 | Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. ( Isojärvi, J; Knip, M; Pakarinen, A; Pylvänen, V, 2006) |
| "Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity." | 1.33 | Drug-induced weight gain. ( Apovian, CM; Ness-Abramof, R, 2005) |
| "Autism is a severe behavioral disorder characterized by pervasive impairments in social interactions, deficits in verbal and nonverbal communication, and stereotyped, repetitive patterns of behaviors and interests." | 1.33 | Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. ( Przewłocki, R; Schneider, T, 2005) |
| "Polycystic ovary syndrome was more common in patients on medication (38%; in 63% on VPA, in 25% on other medication) than in patients off medication (6%) or in controls (11%) (p = 0." | 1.32 | Long-term reproductive endocrine health in young women with epilepsy during puberty. ( Isojärvi, JI; Järvelä, IY; Knip, M; Mikkonen, K; Pakarinen, AJ; Tapanainen, JS; Vainionpää, LK, 2004) |
| "Juvenile myoclonic epilepsy is a common, under-recognised form of epilepsy which is best treated with sodium valproate." | 1.29 | Juvenile myoclonic epilepsy: diagnosis, management and outcome. ( Buchanan, N; Sharpe, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (11.22) | 18.2507 |
| 2000's | 52 (53.06) | 29.6817 |
| 2010's | 28 (28.57) | 24.3611 |
| 2020's | 7 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Mani, B | 1 |
| Nair, PP | 1 |
| Sekhar, A | 1 |
| Kamalanathan, S | 1 |
| Narayan, SK | 1 |
| Kesavan, R | 1 |
| Tunçel, ÖK | 1 |
| Altunkaynak, Z | 1 |
| Bilgici, B | 1 |
| Karaustaoğlu, A | 1 |
| Gümrükçüoğlu, Tİ | 1 |
| Sun, L | 1 |
| Yagoda, S | 1 |
| Yao, B | 1 |
| Graham, C | 1 |
| von Moltke, L | 1 |
| de Mattos, BDS | 1 |
| Soares, MSP | 1 |
| Spohr, L | 1 |
| Pedra, NS | 1 |
| Teixeira, FC | 1 |
| de Souza, AA | 1 |
| Stefanello, FM | 1 |
| Baldissarelli, J | 1 |
| Gamaro, GD | 1 |
| Spanevello, RM | 1 |
| Zhang, H | 1 |
| Lu, P | 1 |
| Tang, HL | 1 |
| Yan, HJ | 1 |
| Jiang, W | 1 |
| Shi, H | 1 |
| Chen, SY | 1 |
| Gao, MM | 1 |
| Zeng, XD | 1 |
| Long, YS | 1 |
| Platzer, M | 1 |
| Fellendorf, FT | 1 |
| Bengesser, SA | 1 |
| Birner, A | 1 |
| Dalkner, N | 1 |
| Hamm, C | 1 |
| Lenger, M | 1 |
| Maget, A | 1 |
| Pilz, R | 1 |
| Queissner, R | 1 |
| Reininghaus, B | 1 |
| Reiter, A | 1 |
| Mangge, H | 1 |
| Zelzer, S | 1 |
| Kapfhammer, HP | 1 |
| Reininghaus, EZ | 1 |
| Sidhu, HS | 1 |
| Srinivas, R | 1 |
| Sadhotra, A | 1 |
| Ferrara, P | 1 |
| Gatto, A | 1 |
| Blasi, V | 1 |
| DI Ruscio, F | 1 |
| Battaglia, D | 1 |
| Joshi, H | 1 |
| Sharma, R | 1 |
| Prashar, S | 1 |
| Ho, J | 1 |
| Thomson, S | 1 |
| Mishra, R | 1 |
| Çiçek, NP | 1 |
| Kamaşak, T | 1 |
| Serin, M | 1 |
| Okten, A | 1 |
| Alver, A | 1 |
| Cansu, A | 2 |
| Bai, X | 1 |
| Xu, C | 1 |
| Wen, D | 1 |
| Chen, Y | 1 |
| Li, H | 3 |
| Wang, X | 2 |
| Zhou, L | 2 |
| Huang, M | 2 |
| Jin, J | 1 |
| Andrade, C | 1 |
| Selim, ME | 1 |
| Al-Ayadhi, LY | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Belcastro, V | 1 |
| D'Egidio, C | 2 |
| Striano, P | 1 |
| Verrotti, A | 8 |
| Chukwu, J | 1 |
| Delanty, N | 1 |
| Webb, D | 1 |
| Cavalleri, GL | 1 |
| Wang, PS | 1 |
| Wu, SL | 1 |
| Ching, HY | 1 |
| Petty, SJ | 1 |
| Kantor, S | 1 |
| Lawrence, KM | 1 |
| Berkovic, SF | 1 |
| Collins, M | 1 |
| Hill, KD | 1 |
| Makovey, J | 1 |
| Sambrook, PN | 1 |
| O'Brien, TJ | 1 |
| Wark, JD | 1 |
| Chen, B | 1 |
| Choi, H | 1 |
| Hirsch, LJ | 1 |
| Moeller, J | 1 |
| Javed, A | 1 |
| Kato, K | 1 |
| Legge, A | 1 |
| Buchsbaum, R | 1 |
| Detyniecki, K | 1 |
| Zhou, Y | 1 |
| Ni, G | 1 |
| Su, Q | 1 |
| Chen, Z | 3 |
| Li, J | 1 |
| Chen, X | 1 |
| Hou, X | 1 |
| Xie, W | 1 |
| Xin, S | 1 |
| Noai, M | 1 |
| Soraoka, H | 1 |
| Kajiwara, A | 1 |
| Tanamachi, Y | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ishitsu, T | 1 |
| Saruwatari, J | 1 |
| Garoufi, A | 1 |
| Vartzelis, G | 1 |
| Tsentidis, C | 1 |
| Attilakos, A | 1 |
| Koemtzidou, E | 1 |
| Kossiva, L | 1 |
| Katsarou, E | 1 |
| Soldatou, A | 1 |
| Hamed, SA | 1 |
| Fida, NM | 1 |
| Hamed, EA | 1 |
| Espinosa, PS | 1 |
| Salazar, JC | 1 |
| Yu, L | 1 |
| Mendiondo, MS | 1 |
| Robertson, WC | 1 |
| Baumann, RJ | 1 |
| Langosch, JM | 1 |
| Drieling, T | 1 |
| Biedermann, NC | 1 |
| Born, C | 1 |
| Sasse, J | 1 |
| Bauer, H | 1 |
| Walden, J | 1 |
| Bauer, M | 1 |
| Grunze, H | 1 |
| Aydin, S | 1 |
| Dag, E | 1 |
| Tohen, M | 3 |
| Vieta, E | 2 |
| Goodwin, GM | 1 |
| Sun, B | 1 |
| Amsterdam, JD | 1 |
| Banov, M | 1 |
| Shekhar, A | 1 |
| Aaronson, ST | 1 |
| Bardenstein, L | 1 |
| Grecu-Gabos, I | 1 |
| Tochilov, V | 1 |
| Prelipceanu, D | 1 |
| Oliff, HS | 1 |
| Kryzhanovskaya, L | 1 |
| Bowden, C | 1 |
| Grosso, S | 2 |
| Mostardini, R | 2 |
| Piccini, B | 1 |
| Balestri, P | 2 |
| Di Marco, G | 1 |
| la Torre, R | 2 |
| Pelliccia, P | 1 |
| Chiarelli, F | 7 |
| Trotta, D | 2 |
| Mohn, A | 3 |
| Sharpe, C | 2 |
| Wolfson, T | 1 |
| Trauner, DA | 1 |
| Novick, D | 1 |
| Gonzalez-Pinto, A | 1 |
| Haro, JM | 1 |
| Bertsch, J | 1 |
| Reed, C | 1 |
| Perrin, E | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 1 |
| Prodam, F | 1 |
| Bellone, S | 1 |
| Casara, G | 1 |
| De Rienzo, F | 1 |
| Grassino, EC | 1 |
| Bonsignori, I | 1 |
| Demarchi, I | 1 |
| Rapa, A | 1 |
| Radetti, G | 1 |
| Bona, G | 1 |
| Bond, DJ | 1 |
| Kauer-Sant'Anna, M | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Bowden, CL | 3 |
| Mosolov, S | 1 |
| Hranov, L | 1 |
| Chen, E | 1 |
| Habil, H | 1 |
| Kongsakon, R | 1 |
| Manfredi, R | 1 |
| Lin, HN | 1 |
| Masuccio, F | 1 |
| Chiavaroli, V | 1 |
| de Giorgis, T | 1 |
| Giannini, C | 1 |
| Gaspari, CN | 1 |
| Guerreiro, CA | 1 |
| Coppola, G | 1 |
| Luisi, S | 1 |
| Matera, M | 1 |
| Barlocco, EG | 1 |
| Casarosa, E | 1 |
| Petraglia, F | 1 |
| Velizarova, R | 1 |
| Genton, P | 1 |
| Serdaroglu, A | 2 |
| Camurdan, O | 1 |
| Hırfanoğlu, T | 1 |
| Cinaz, P | 1 |
| Meral, C | 1 |
| Cekmez, F | 1 |
| Vurucu, S | 1 |
| Tascılar, E | 1 |
| Pirgon, O | 1 |
| Canpolat, FE | 1 |
| Ipcioglu, OM | 1 |
| Aydemir, G | 1 |
| Aydınoz, S | 1 |
| Kanemura, H | 1 |
| Sano, F | 1 |
| Maeda, Y | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Sheehan, DV | 1 |
| Harnett-Sheehan, K | 1 |
| Hidalgo, RB | 1 |
| Janavs, J | 1 |
| McElroy, SL | 1 |
| Amado, D | 1 |
| Suppes, T | 2 |
| Ekholm, B | 1 |
| Udd, M | 1 |
| Gustafsson, U | 1 |
| Luef, G | 2 |
| Abraham, I | 1 |
| Hoppichler, F | 3 |
| Trinka, E | 2 |
| Unterberger, I | 2 |
| Bauer, G | 2 |
| Lechleitner, M | 2 |
| Akdeniz, F | 1 |
| Taneli, F | 1 |
| Noyan, A | 1 |
| Yüncü, Z | 1 |
| Vahip, S | 1 |
| Caksen, H | 1 |
| Deda, G | 1 |
| Berberoğlu, M | 1 |
| Gilmor, ML | 1 |
| Skelton, KH | 1 |
| Nemeroff, CB | 1 |
| Owens, MJ | 1 |
| Biton, V | 1 |
| Levisohn, P | 1 |
| Hoyler, S | 1 |
| Vuong, A | 1 |
| Hammer, AE | 1 |
| Wirrell, EC | 1 |
| Bosnak, M | 1 |
| Dikici, B | 1 |
| Haspolat, K | 1 |
| Dagli, A | 1 |
| Dikici, S | 1 |
| Morrell, MJ | 1 |
| Isojärvi, J | 4 |
| Taylor, AE | 1 |
| Dam, M | 1 |
| Ayala, R | 1 |
| Gomez, G | 1 |
| O'Neill, F | 1 |
| Tennis, P | 1 |
| Messenheimer, J | 1 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| Basile, VS | 1 |
| Srinivasan, J | 1 |
| Kennedy, SH | 1 |
| Mikkonen, K | 1 |
| Vainionpää, LK | 1 |
| Pakarinen, AJ | 1 |
| Knip, M | 3 |
| Järvelä, IY | 1 |
| Tapanainen, JS | 1 |
| Isojärvi, JI | 1 |
| Henry, CA | 1 |
| Zamvil, LS | 1 |
| Lam, C | 1 |
| Rosenquist, KJ | 1 |
| Ghaemi, SN | 1 |
| Greco, R | 1 |
| Latini, G | 1 |
| De Simone, M | 2 |
| Ding, MP | 1 |
| Bao, YY | 1 |
| Liu, ZR | 1 |
| Xu, LL | 1 |
| Schneider, T | 1 |
| Przewłocki, R | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Morland, C | 1 |
| Boldingh, KA | 1 |
| Iversen, EG | 1 |
| Hassel, B | 1 |
| Klein, KM | 1 |
| Hamer, HM | 1 |
| Reis, J | 1 |
| Schmidtke, J | 1 |
| Oertel, WH | 1 |
| Theisen, FM | 1 |
| Hebebrand, J | 1 |
| Rosenow, F | 1 |
| Hellings, JA | 1 |
| Weckbaugh, M | 1 |
| Nickel, EJ | 1 |
| Cain, SE | 1 |
| Zarcone, JR | 1 |
| Reese, RM | 1 |
| Hall, S | 1 |
| Ermer, DJ | 1 |
| Tsai, LY | 1 |
| Schroeder, SR | 1 |
| Cook, EH | 1 |
| Ness-Abramof, R | 1 |
| Apovian, CM | 1 |
| Maggioni, F | 1 |
| Ruffatti, S | 1 |
| Dainese, F | 1 |
| Mainardi, F | 1 |
| Zanchin, G | 1 |
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Feldman, S | 1 |
| Yu, Y | 1 |
| McMahon, RP | 1 |
| Richardson, CM | 1 |
| Aydin, K | 1 |
| Okuyaz, C | 1 |
| Bideci, A | 1 |
| Gucuyener, K | 1 |
| Pylvänen, V | 2 |
| Pakarinen, A | 2 |
| McCabe, PH | 1 |
| Michel, NC | 1 |
| McNew, CD | 1 |
| Lehman, EB | 1 |
| Aldenkamp, A | 1 |
| Vigevano, F | 1 |
| Arzimanoglou, A | 1 |
| Covanis, A | 1 |
| Correll, CU | 1 |
| Carlson, HE | 1 |
| El-Khatib, F | 1 |
| Rauchenzauner, M | 2 |
| Naser, A | 1 |
| Waldmann, M | 1 |
| Luef, GJ | 1 |
| Prabhakar, S | 1 |
| Sahota, P | 1 |
| Kharbanda, PS | 1 |
| Siali, R | 1 |
| Jain, V | 1 |
| Lal, V | 1 |
| Khurana, D | 1 |
| Tsai, LK | 1 |
| Yang, CC | 1 |
| Hwu, WL | 1 |
| Jedrzejczak, J | 1 |
| Kuncíková, M | 1 |
| Magureanu, S | 1 |
| Reynolds, MF | 1 |
| Sisk, EC | 1 |
| Rasgon, NL | 1 |
| Haberlandt, E | 1 |
| Scholl-Bürgi, S | 1 |
| Ernst, B | 1 |
| Karall, D | 1 |
| Ebenbichler, CF | 1 |
| Rostasy, K | 1 |
| Gungor, S | 1 |
| Yücel, G | 1 |
| Akinci, A | 1 |
| Tabel, Y | 1 |
| Ozerol, IH | 1 |
| Yologlu, S | 1 |
| Buchanan, N | 1 |
| Narotsky, MG | 1 |
| Francis, EZ | 1 |
| Kavlock, RJ | 1 |
| Easter, D | 1 |
| O'Bryan-Tear, CG | 1 |
| Verity, C | 1 |
| Corman, CL | 1 |
| Leung, NM | 1 |
| Guberman, AH | 1 |
| Sharma, S | 1 |
| Jacobs, HS | 1 |
| Sundqvist, A | 1 |
| Tomson, T | 1 |
| Lundkvist, B | 1 |
| Basciani, F | 2 |
| Morresi, S | 1 |
| de Martino, M | 1 |
| Morgese, G | 2 |
| Novak, GP | 1 |
| Maytal, J | 1 |
| Alshansky, A | 1 |
| Eviatar, L | 1 |
| Sy-Kho, R | 1 |
| Siddique, Q | 1 |
| Chang, KD | 1 |
| Ketter, TA | 1 |
| Demir, E | 1 |
| Aysun, S | 1 |
| Sajatovic, M | 1 |
| Brescan, DW | 1 |
| Perez, DE | 1 |
| DiGiovanni, SK | 1 |
| Hattab, H | 1 |
| Ray, JB | 1 |
| Bingham, CR | 1 |
| Sanford, MG | 1 |
| Ryan, C | 1 |
| Cummings, AD | 1 |
| Hunt, A | 1 |
| Hackes, B | 1 |
| Breum, L | 1 |
| Astrup, A | 1 |
| Gram, L | 1 |
| Andersen, T | 1 |
| Stokholm, KH | 1 |
| Christensen, NJ | 1 |
| Werdelin, L | 1 |
| Madsen, J | 1 |
| Strakowski, SM | 1 |
| Hudson, JI | 1 |
| Keck, PE | 1 |
| Wilson, DR | 1 |
| Frankenburg, FR | 1 |
| Alpert, JE | 1 |
| Teschke, GC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for valproic acid and Weight Gain
| Article | Year |
|---|---|
Antidepressant action of atypical antipsychotics: focus on ziprasidone monotherapy, with a few twists in the tale.
Topics: Adult; Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Huma | 2013 |
Metabolic and endocrine effects of valproic acid chronic treatment.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperinsulinism; Insulin Resistance; Leptin; Metabolic Syndrome; | 2013 |
Weight change, genetics and antiepileptic drugs.
Topics: Animals; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Huma | 2014 |
Valproate-induced insulin resistance and obesity in children.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Insulin Resistance; Obesity; Valproic Acid; Weight Gain | 2009 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
Topics: Androgens; Anticonvulsants; Epilepsy; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; | 2011 |
Valproate.
Topics: Antimanic Agents; Bipolar Disorder; Drug Interactions; Humans; Lamotrigine; Lithium Compounds; Progn | 2003 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; De | 2005 |
Role of valproate across the ages. Treatment of epilepsy in children.
Topics: Anticonvulsants; Child; Epilepsies, Myoclonic; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epi | 2006 |
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Dibenzothiazepines; Drug Administration Schedule; Endocrine | 2006 |
Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral; Epilepsy; Female; Hormone | 2007 |
23 trials available for valproic acid and Weight Gain
| Article | Year |
|---|---|
Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
Topics: Adiponectin; Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Cholesterol; Choles | 2017 |
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Female; Humans; Hypotension | 2008 |
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2008 |
Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Femal | 2010 |
Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy.
Topics: Adolescent; Anticonvulsants; Behavior Therapy; Body Mass Index; Child; Epilepsy; Female; Humans; Hyp | 2012 |
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Dibenzothiazepines; Doub | 2013 |
Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2012 |
Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Epilepsy; Fem | 2002 |
Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Body Mass Index; Child; Double-Blind Metho | 2003 |
Antipsychotic-induced weight gain: bipolar disorder and leptin.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body M | 2003 |
Long-term outcome with divalproex in children and adolescents with bipolar disorder.
Topics: Adolescent; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; | 2003 |
Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate.
Topics: Adolescent; alpha-Tocopherol; Anticonvulsants; Antioxidants; beta Carotene; Body Weight; Carotenoids | 2004 |
A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Child; Child Development Disorders, Pervasive; Doubl | 2005 |
Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up.
Topics: Adrenergic beta-Antagonists; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants | 2005 |
Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate.
Topics: Anticonvulsants; Blood Glucose; Body Mass Index; Child; Child, Preschool; Epilepsy; Female; Humans; | 2005 |
Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
Topics: Anticonvulsants; Delayed-Action Preparations; Epilepsy; Follow-Up Studies; Humans; Patient Complianc | 2006 |
An observational study of first-line valproate monotherapy in focal epilepsy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Brain Diseases; Child; Delayed-Action Preparations; | 2008 |
The role of ghrelin in weight gain and growth in epileptic children using valproate.
Topics: Adolescent; Anticonvulsants; Blood Glucose; Body Height; Body Mass Index; Body Weight; C-Peptide; Ch | 2007 |
Weight gain with valproate or carbamazepine--a reappraisal.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cross-Over Studies; Dose-Respon | 1997 |
Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male; Middle Aged | 1997 |
Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study.
Topics: Adolescent; Adult; Anticonvulsants; Area Under Curve; Disease-Free Survival; Dose-Response Relations | 1998 |
Weight gain associated with valproate in childhood.
Topics: Adolescent; Anticonvulsants; Blood Glucose; Carnitine; Child; Child, Preschool; Drug Therapy, Combin | 2000 |
Quetiapine alone and added to a mood stabilizer for serious mood disorders.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Dibenzothiazepi | 2001 |
63 other studies available for valproic acid and Weight Gain
| Article | Year |
|---|---|
CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study.
Topics: Anticonvulsants; Cytochrome P-450 CYP2C19; Epilepsy; Genetic Association Studies; Genotype; Glucuron | 2021 |
Increased growth hormone secretagogue receptor-1a (GHSR-1a) in hypothalamus during olanzapine treatment in rats.
Topics: Adiponectin; Animals; Ghrelin; Hypothalamus; Interleukin-6; Leptin; Olanzapine; Rats; Receptors, Ghr | 2022 |
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Drug Combinations; Drug Interactions; Female; Humans; L | 2020 |
Quercetin prevents alterations of behavioral parameters, delta-aminolevulinic dehydratase activity, and oxidative damage in brain of rats in a prenatal model of autism.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain Chemistry; Female; Motor Activity; Neuroprotectiv | 2020 |
Valproate-Induced Epigenetic Upregulation of Hypothalamic Fto Expression Potentially Linked with Weight Gain.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Anticonvulsants; Dose-Response Relationship, | 2021 |
The Relationship Between Food Craving, Appetite-Related Hormones and Clinical Parameters in Bipolar Disorder.
Topics: Acylation; Adult; Anthropometry; Appetite; Bipolar Disorder; Craving; Cross-Sectional Studies; Fast | 2020 |
The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Seizures; Valproic Acid; W | 2022 |
Differential Expression of Synapsin I and II upon Treatment by Lithium and Valproic Acid in Various Brain Regions.
Topics: Animals; Brain; Gene Expression; Lithium Compounds; Male; Psychotropic Drugs; Random Allocation; Rat | 2018 |
The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
Topics: Adolescent; Anticonvulsants; Biomarkers; Blood Glucose; Body Mass Index; Child; Epilepsy; Fructose; | 2018 |
Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Body Mass Index; Body Weight; CD36 Antige | 2018 |
Possible ameliorative effect of breastfeeding and the uptake of human colostrum against coeliac disease in autistic rats.
Topics: Animal Nutritional Physiological Phenomena; Animals; Animals, Suckling; Autistic Disorder; Autoantib | 2013 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Diagnostic and Statistical Manua | 2014 |
Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.
Topics: Abdominal Fat; Absorptiometry, Photon; Adult; Anticonvulsants; Blood Pressure; Body Composition; Bod | 2014 |
Cosmetic side effects of antiepileptic drugs in adults with epilepsy.
Topics: Acne Vulgaris; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Gingival | 2015 |
Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.
Topics: Adolescent; Adult; AMP-Activated Protein Kinases; Anticonvulsants; Body Weight; Chromatography, High | 2015 |
Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Carbamazepine; Child; Cytochrome P-450 CYP2C19; Epilep | 2016 |
Weight gain in children on oxcarbazepine monotherapy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Carbamazepine; Child; Child, Preschool; Epilepsy; Fema | 2016 |
States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Mass Index; Carbamazepine; Case-Control Studies; Chil | 2009 |
Lack of valproic acid-associated weight gain in prepubertal children.
Topics: Adolescent; Anticonvulsants; Body Height; Body Mass Index; Body Weight; Carbamazepine; Child; Child, | 2008 |
Does ghrelin really increase in epileptic children treated with valproate?
Topics: Anticonvulsants; Child; Clinical Laboratory Techniques; Epilepsy; Ghrelin; Humans; Molecular Weight; | 2008 |
Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy.
Topics: Age Factors; Blood Glucose; Body Mass Index; Child, Preschool; Cholesterol; Epilepsy; Female; Follow | 2009 |
Nonalcoholic fatty liver disease during valproate therapy.
Topics: Anticonvulsants; Body Mass Index; Child; Epilepsy; Fatty Liver; Fatty Liver, Alcoholic; Female; Huma | 2009 |
Weight gain in children treated with valproate.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Child; Child, Preschool; Epilepsy; Female; Humans; Lon | 2009 |
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Female; Gastroint | 2009 |
Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid.
Topics: Age Factors; Anticonvulsants; Body Height; Body Mass Index; Carbamazepine; Child; Depression, Chemic | 2010 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Weight gain and insulin resistance in children treated with valproate: the influence of time.
Topics: Anticonvulsants; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Homeostas | 2010 |
Modification in body weight associated with antiepileptic drugs.
Topics: Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Female; Humans; Male; Valproic Aci | 2010 |
Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Immunoassay; Leptin; Male; Obesity; Pregnanolone; | 2011 |
Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Diagnosis, Differential; Dose-Response Relationship, D | 2010 |
Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate.
Topics: Adolescent; Child; Child, Preschool; Epilepsy; Galanin; Ghrelin; Humans; Hydrocortisone; Insulin; Le | 2011 |
New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid.
Topics: Adipokines; Adiponectin; Adolescent; Anticonvulsants; Apelin; Child; Female; Humans; Intercellular S | 2011 |
Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Endocrine System; Epilepsy; Fema | 2003 |
Does long-term use of valproate cause weight gain in prepubertal epileptic children?
Topics: Anticonvulsants; Body Mass Index; Child; Epilepsy; Female; Humans; Leptin; Male; Time; Valproic Acid | 2002 |
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems.
Topics: Adrenocorticotropic Hormone; Animals; Antimanic Agents; Autoradiography; Corticosterone; Corticotrop | 2003 |
Valproic acid-associated weight gain in older children and teens with epilepsy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Child; Epilepsy; Female; Follow-Up Studies; Humans; Ma | 2003 |
Do epileptic children treated with valproate have a risk of excessive weight gain?
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; Obesi | 2003 |
Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.
Topics: Adult; Analysis of Variance; Androgens; Confidence Intervals; Cross-Sectional Studies; Epilepsy; Fem | 2003 |
Long-term reproductive endocrine health in young women with epilepsy during puberty.
Topics: Adolescent; Anticonvulsants; Child; Cohort Studies; Comorbidity; Epilepsy; Female; Finland; Follow-U | 2004 |
[Insulin resistance in epileptic patients during treatment of valproic acid].
Topics: Adult; Body Mass Index; Epilepsy; Female; Humans; Insulin Resistance; Male; Valproic Acid; Weight Ga | 2004 |
Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Attention; Autistic Disorder; Behavior, Animal; Disc | 2005 |
Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake.
Topics: Adenosine Triphosphate; Animals; Biological Transport; Carbon Radioisotopes; Cell Death; Deoxyglucos | 2004 |
Weight change in monozygotic twins treated with valproate.
Topics: Adolescent; Adult; Anticonvulsants; Child, Preschool; Diseases in Twins; Epilepsy; Female; Humans; M | 2005 |
Drug-induced weight gain.
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Obesity; Psychotropic Drugs; Risperidone; Valproic Ac | 2005 |
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Anxiety; Blood Glucose; Brief Psychi | 2006 |
Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
Topics: Adult; Anticonvulsants; Body Mass Index; Epilepsy; Female; Humans; Hyperinsulinism; Insulin; Lipopro | 2006 |
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
Topics: Adult; Anticonvulsants; Blood Glucose; C-Peptide; Epilepsy; Fasting; Female; Humans; Hyperinsulinism | 2006 |
Valproate, weight gain and carbohydrate craving: a gender study.
Topics: Adult; Anticonvulsants; Appetite; Body Mass Index; Dietary Carbohydrates; Epilepsy; Female; Glucose; | 2007 |
Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study.
Topics: Body Mass Index; Epilepsy; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Indians, | 2007 |
Valproic acid treatment in six patients with spinal muscular atrophy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship | 2007 |
Adiponectin and visfatin concentrations in children treated with valproic acid.
Topics: Adiponectin; Adipose Tissue; Age Factors; Anticonvulsants; Blood Glucose; Child; Epilepsy; Female; H | 2008 |
Juvenile myoclonic epilepsy: diagnosis, management and outcome.
Topics: Adolescent; Adult; Alcohol Drinking; Anticonvulsants; Carbamazepine; Epilepsies, Myoclonic; Female; | 1995 |
Developmental toxicity and structure-activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats.
Topics: Acids; Animals; Behavior, Animal; Body Weight; Female; Male; Mice; Pregnancy; Rats; Rats, Sprague-Da | 1994 |
Polycystic ovary syndrome associated with treatment with the anticonvulsant sodium valproate.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Polycystic Ovary Syndrome; Pregnancy; Valproic Aci | 1997 |
Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid.
Topics: Adolescent; Androgens; Anticonvulsants; Blood Glucose; Body Mass Index; Epilepsy; Female; Follicle S | 1999 |
Risk of excessive weight gain in epileptic children treated with valproate.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Child; Child, Preschool; Dose-Response Relation | 1999 |
Mood stabilizer augmentation with olanzapine in acutely manic children.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepin | 2000 |
[The dangers of valproate in women].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Humans; Hyperandro | 1998 |
Protocols for identifying drug-nutrient interactions in patients: the role of the dietitian.
Topics: Adolescent; Adult; Anticonvulsants; Biotin; Calcium; Carnitine; Dietetics; Edema; Folic Acid; Food-D | 2002 |
Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.
Topics: Androgens; Anticonvulsants; Blood Glucose; Body Mass Index; Child; Epilepsy; Female; Follicle Stimul | 2002 |
Metabolic changes during treatment with valproate in humans: implication for untoward weight gain.
Topics: Adult; Catecholamines; Electrolytes; Fatty Acids, Nonesterified; Female; Glucose; Humans; Male; Thyr | 1992 |
Four cases of obstructive sleep apnea associated with treatment-resistant mania.
Topics: Adult; Bipolar Disorder; Clonazepam; Female; Follow-Up Studies; Hospitalization; Humans; Lithium; Mi | 1991 |